Search research articles
Contact Us
Filters
Showing results (431-440 of 590) with videos related to
Page
of 59
Sort By:
The Journal of Sexual Medicine
|
October 15, 2013
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift
Kevin T McVary, Steven N Gange, Neal D Shore, et al.
European Urology Oncology
|
June 16, 2019
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review
Stephen B Williams, Mohamed D Ray-Zack, Hogan K Hudgins, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Neal D Shore, Ugo De Giorgi, Matko Kalac, et al.
JAMA Oncology
|
June 16, 2022
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
Neal D Shore, Joseph Renzulli, Neil E Fleshner, et al.
Surgery
|
August 2, 2011
Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis
Skye C Mayo, Jennifer E Heckman, Andrew D Shore, et al.
Archives of Surgery (Chicago, Ill. : 1960)
|
August 18, 2010
Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery
Martin A Makary, Jeanne M Clark, Jeanne M Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Eric J Small, Raymond S Lance, Thomas A Gardner, et al.
Future Oncology (London, England)
|
January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
Future Oncology (London, England)
|
August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
JAMA Oncology
|
March 7, 2024
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Daniel E Spratt, Daniel J George, Neal D Shore, et al.
Page
of 59
Search research articles
Search
Showing results (431-440 of 590) with videos related to
Sort By:
Page
of 59
The Journal of Sexual Medicine
|
October 15, 2013
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift
Kevin T McVary, Steven N Gange, Neal D Shore, et al.
European Urology Oncology
|
June 16, 2019
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review
Stephen B Williams, Mohamed D Ray-Zack, Hogan K Hudgins, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Neal D Shore, Ugo De Giorgi, Matko Kalac, et al.
JAMA Oncology
|
June 16, 2022
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
Neal D Shore, Joseph Renzulli, Neil E Fleshner, et al.
Surgery
|
August 2, 2011
Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis
Skye C Mayo, Jennifer E Heckman, Andrew D Shore, et al.
Archives of Surgery (Chicago, Ill. : 1960)
|
August 18, 2010
Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery
Martin A Makary, Jeanne M Clark, Jeanne M Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Eric J Small, Raymond S Lance, Thomas A Gardner, et al.
Future Oncology (London, England)
|
January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
Future Oncology (London, England)
|
August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Neeraj Agarwal, Arun Azad, Neal D Shore, et al.
JAMA Oncology
|
March 7, 2024
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Daniel E Spratt, Daniel J George, Neal D Shore, et al.
Page
of 59